Fundraising Fox神拓生物
1 known investors
Find your way into 神拓生物
Sign up to see every warm intro you have to 神拓生物
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 神拓生物 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Santo Biopharma is a drug development company building next-generation lentiviral vector in vivo gene therapies for rare diseases and cancer, including neurofibromatosis, meningioma, and malignant mesothelioma. It develops a fifth-generation lentiviral vector delivery system and serum-free production platforms to support gene therapy research.
Founders & leadership
周
周露Founder
NR
Nick RodgersHonorary Chairman
张
张放CTO
王
王志萍CSO
铁
铁柳CMC Lead
李
李蝶CFO
Investors · 1
Frequently asked questions
- What does 神拓生物 do?
- Santo Biopharma is a drug development company building next-generation lentiviral vector in vivo gene therapies for rare diseases and cancer, including neurofibromatosis, meningioma, and malignant mesothelioma. It develops a fifth-generation lentiviral vector delivery system and serum-free production platforms to support gene therapy research.
- Who are 神拓生物's investors?
- 神拓生物's investors include TriWise Capital.